Elsevier

Surgery

Volume 121, Issue 6, June 1997, Pages 601-605
Surgery

Original communication
Sestamibi versus thallium subtraction scintigraphy in parathyroid localization: A prospective comparative study in patients with predominantly mild primary hyperparathyroidism

https://doi.org/10.1016/S0039-6060(97)90046-5Get rights and content

Abstract

Background. Technetium 99m sestamibi was recently introduced for the preoperative localization of abnormal parathyroid glands in patients with primary hyperparathyroidism with promising results. However, the sensitivity of sestamibi and thallium to detect abnormal parathyroid glands is partly dependent on the gland size. In this study we compared the sensitivity of sestamibi subtraction scintigraphy with thallium subtraction scintigraphy in patients with predominantly mild increase in serum calcium level.

Methods. Thirty-nine patients with primary hyperparathyroidism were included. The mean (± SD) serum level of calcium was 2.75 ± 0.17 mmol/L. In 28 (72%) of the patients the serum level of calcium was less than 2.85 mmol/L. These patients were classified as having mild abnormalities in serum calcium. All patients were investigated before operation with both sestamibi and thallium subtraction scintigraphy.

Results. In two patients autonomous thyroid adenomas precluded subtraction scintigraphy. Sestamibi subtraction scintigraphy correctly localized 31 (86%) of 36 parathyroid adenomas compared with only 17 (47%) of 36 by thallium subtraction scintigraphy (p < 0.001). There was one false- positive result in the sestamibi group because of a thyroid adenoma, and two of the scans were negative. Both the sestamibi and the thallium subtraction scintigraphy localized one single enlarged gland in all three patients with multiple gland involvement. In no case was multiglandular disease predicted.

Conclusions. Sestamibi subtraction scintigraphy is superior to thallium subtraction scintigraphy and has a high sensitivity to localize a solitary parathyroid adenoma in patients with mild increase in serum calcium level. The sensitivity decreases in patients with multiglandular parathyroid disease and concomitant thyroid nodular abnormalities.

References (23)

  • BK Mitchell et al.

    Localization studies in patients with hyperparathyroidism

    Surg Clin North Am

    (1995)
  • M McBiles et al.

    Sestamibi parathyroid imaging

  • JP Wei et al.

    Analysis in operative time for primary hyper-parathyroidism using localization with technetium 99m sestamibi scan

    Am J Surg

    (1995)
  • DL Miller

    Pre-operative localization and interventional treatment of parathyroid tumors: when and how

    World J Surg

    (1991)
  • JL Doppman et al.

    Localization of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery

    J Bone Miner Res

    (1991)
  • AJ Coakley et al.

    99mTc sestamibi a new agent for parathyroid imaging

    Nucl Med Commun

    (1989)
  • R Taillefer

    99mTc sestamibi parathyroid scintigraphy

  • MJ O'Doherty et al.

    Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies

    J Nucl Med

    (1992)
  • GG Winzelberg et al.

    Parathyroid adenomas evaluated by Tl-201/Tc-99m pertechnetate subtraction scintigraphy and high resolution ultrasonography

    Radiology

    (1985)
  • VS Lee et al.

    Hyperparathyroidism in high-risk surgical patients: evaluation with double-phase technetium-99m sestamibi imaging

    Radiology

    (1995)
  • GG Winzelberg

    Parathyroid imaging

    Ann Intern Med

    (1987)
  • Cited by (59)

    • Parathyroid Imaging

      2023, Seminars in Nuclear Medicine
    • Preoperative, Intraoperative, and Postoperative Parathyroid Pathology: Clinical Pathologic Collaboration for Optimal Patient Management

      2023, Surgical Pathology Clinics
      Citation Excerpt :

      Atypical parathyroid adenomas were usually less pronounced in size but could be adherent to surrounding tissues (without overt signs of invasion).31 Microscopically, a diagnosis of atypical parathyroid adenoma was rendered with the observance of worrisome features including mitoses, desmoplastic reaction, nuclear atypia, necrosis, monotonous sheet-like or trabecular growth, fibrosis, and tumor cells in the capsule.4,30–35 Histologic signs of invasion (perineural, intravascular, lymphatic, or pericapsular) or metastasis upgraded the diagnosis to a parathyroid carcinoma.30

    • Parathyroid imaging

      2011, Radiologic Clinics of North America
      Citation Excerpt :

      Adenomatous and hyperplastic parathyroid tissue show more avid uptake of 99mTc-sestamibi although initially this activity can be obscured by uptake from the adjacent thyroid gland. Subtraction techniques that use a thyroid agent such as 99mTc-pertechnitate or 123I coregistered with a 99mTc-sestamibi image attempt to improve conspicuity of parathyroid tissue by subtracting out the adjacent thyroid uptake.52,53 The observation that abnormal parathyroid tissue commonly retains 99mTc-sestamibi longer than thyroid tissue has led to the widespread use of delayed imaging to improve upon the conspicuity of hyperfunctioning parathyroid tissue.

    • Endocrine System

      2022, The Pathophysiologic Basis of Nuclear Medicine: Fourth Edition
    View all citing articles on Scopus

    Supported by grants from the Swedish Society of Medicine and from the Crafoord Foundation, Lund, Sweden.

    View full text